



BIA Response to Meaningful Vote

15 January 2019

Steve Bates OBE, CEO of the BIA said: “As we have stressed before a ‘no-deal’ disorderly Brexit must be avoided as it will negatively impact patients, public health and the life sciences sector. Medicines and vaccines have complex and integrated manufacturing supply chains and patient safety procedures. Despite the tremendous efforts of companies to prepare, we repeat that some medicines can’t be stockpiled and we are still lacking detail on what transport operating systems companies will need to use in a ‘no deal’ scenario.

“Time is running out till we reach a ‘no deal’ cliff-edge Brexit which will increase the possibility of medicines shortages for UK patients, that is a risk and it is why the BIA is calling on Government to rule out a ‘no deal’ Brexit.”